Analyst Reco. Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
21.74 ^USD	-1.23%		-2.90%	+1.30%

Jun. 13	Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors and Chairperson of Audit Committee	CI
Jun. 03	Denali Therapeutics' Enzyme Replacement Therapy Picked for FDA's START Pilot Program; Shares Rise	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating	May. 08	MT
Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating	May. 08	MT
UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	Apr. 09	MT
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	Apr. 03	MT
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating	Feb. 28	MT
Citigroup Initiates Denali Therapeutics With Buy Rating, Price Target is $32	Dec. 13	MT
B. Riley Initiates Denali Therapeutics at Buy With $38 Price Target	23-09-06	MT
Wedbush Lowers Denali Therapeutics' Price Target to $31 From $37 Following Pipeline Updates, Keeps Outperform Rating	23-08-09	MT
Oppenheimer Adjusts Denali Therapeutics Price Target to $68 From $70, Maintains Outperform Rating	23-06-06	MT
Wedbush Trims Denali Therapeutics' Price Target to $37 From $38, Notes Slightly Higher Share Count; Keeps Outperform Rating	23-05-09	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $63 From $61, Maintains Overweight Rating	23-04-12	MT
Oppenheimer Adjusts Denali Therapeutics' Price Target to $70 From $85, Maintains Outperform Rating	23-03-02	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $61 From $65, Maintains Overweight Rating	23-03-01	MT
Evercore ISI Adjusts Price Target on Denali Therapeutics to $50 From $80, Maintains Outperform Rating	23-02-28	MT
Wedbush Lowers Denali Therapeutics' PT to $38 From $46, Keeps Outperform Rating	23-02-28	MT
SVB Securities Initiates Denali Therapeutics at Outperform With $50 Price Target	23-01-30	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $65 From $60, Maintains Overweight Rating	23-01-25	MT
Cowen Initiates Denali Therapeutics With Outperform Rating	22-12-05	MT
Morgan Stanley Adjusts Price Target on Denali Therapeutics to $60 From $67, Maintains Overweight Rating	22-11-08	MT
Berenberg Bank Adjusts Denali Therapeutics Price Target to $50 From $39, Maintains Buy Rating	22-11-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Analyst Reco.

Filters